Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SET: Tasimelteon in Non-24-Hour Sleep-Wake Disorder
NCT01163032Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Aug 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of tasimelteon in Non-24-hour sleep-wake disorder (N24SWD), sponsored by Vanda Pharmaceuticals Inc.. Started Aug 2010; status: completed.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)
Beyond the preview
Go deeper on NCT01163032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163032.